EDS • PO Box 13029 • Sacramento, CA • 95813-4029

www.medi-cal.ca.gov

Billing and Policy Pharmacy Bulletin 573

December 2003

ContentsMedi-Cal List of Contract Drugs1Unlisted Wheelchairs, Accessories, and Replacement Parts5Intravenous Compound Drug Claims5Medical Supply Billing Codes5Pharmacy Self-Certification5

Medi-Cal List of Contract Drugs: Update

The following provider manual sections have been updated: *Drugs: Contract Drugs List Part 1 – Prescription Drugs* and *Drugs: Contract Drugs List Part 4 – Therapeutic Classifications.*

Additions, effective October 20, 2003

| <u>Drug</u> | Size and/or Strength | Billing Unit | |
|---------------------------|----------------------|-------------------------|--|
| ‡ * FOSAMPRENAVIR CALCIUM | | | |
| Tablets | 700 mg | ea | |
| | | 1.6. 1.6. 1.6. (4.10.0) | |

^{*} Restricted to use as combination therapy in the treatment of Human Immunodeficiency Virus (HIV) infection.

‡ Drug is exempt from the monthly drug claim line limit.

Please see Contract Drugs, page 3

EDS/MEDI-CAL HOTLINES

| Border Providers | |
|--|----------------|
| Computer Media Claims (CMC) | (916) 636-1100 |
| DHS Medi-Cal Fraud Hotline | 1-800-822-6222 |
| Health Access Programs (HAP) – OB, CPSP, Family PACT, BCEDP Providers. | 1-800-257-6900 |
| POS/Internet Help Desk | 1-800-427-1295 |
| Telephone Service Center (TSC) | 1-800-541-5555 |
| Provider Telecommunications Network (PTN) | 1-800-786-4346 |
| Specialty Programs | 1-800-541-7747 |

For a complete listing of specialty programs and hours of operation, please refer to the Medi-Cal Directory in the provider manual.



MEDI-CAL FRAUD COSTS TAXPAYERS MILLIONS EACH YEAR AND CAN ENDANGER THE HEALTH OF CALIFORNIANS.

HELP PROTECT MEDI-CAL AND YOURSELF BY REPORTING YOUR OBSERVATIONS TODAY.

DHS MEDI-CAL FRAUD HOTLINE 1-800-822-6222

THE CALL IS FREE AND YOU CAN REMAIN ANONYMOUS.

Knowingly participating in fraudulent activities can result in prosecution and jail time. Help prevent Medi-Cal fraud.

Contract Drugs (continued)

Additions, effective January 1, 2004

| Drug | Size and/or Strengt | t <u>h</u> | Billing Unit |
|---|---------------------|------------|--------------|
| DARBEPOETIN ALFA | | | |
| * Injection | 25 mcg | | сс |
| | 40 mcg | | cc |
| | 60 mcg | | cc |
| | 100 mcg | | cc |
| | 150 mcg | | cc |
| | 200 mcg | | CC |
| * Injection, prefilled syringe | 60 mcg | 0.3 cc | cc |
| | 100 mcg | 0.5 cc | сс |
| | 200 mcg | 0.4 cc | CC |
| | 300 mcg | 0.6 cc | CC |
| * Restricted to use for the treatme with non-myeloid malignancies w chemotherapy. | | | |
| DUTASTERIDE | | | |
| + Capsules | 0.5 mg | | ea |
| ROSIGLITAZONE MALEATE/METF | ORMIN HCL | | |
| + Tablets | 1 mg/500 mg | | ea |
| | 2 mg/500 mg | | ea |
| | 4 mg/500 mg | | ea |
| | 2 mg/1000 mg | | ea |
| | 4 mg/1000 mg | | ea |

Changes, effective January 1, 2004

| Drug | Size and/or Strength | Billing Unit |
|---|----------------------|--------------|
| MOXIFLOXACIN HCL Ophthalmic Solution | <u>0.5 %</u> | <u>cc</u> |
| ROSIGLITAZONE MALEATE | | |
| + Tablets | 2 mg | ea |
| | 4 mg | ea |
| | 8 mg | ea |
| | • | |

⁺ Frequency of billing requirement.

Please see Contract Drugs, page 4

Contract Drugs (continued)

Changes, effective February 1, 2004

| Drug | Size and/or Stren | <u>ngth</u> | Billing Unit |
|---|----------------------------|------------------------|-------------------|
| AMOXICILLIN/CLAVULANATE POTASS * Tablets, oral | 1 Gm | | <u>ea</u> |
| * Restricted to a maximum dispe | nsing quantity of te | n (10) tablets and a m | aximum of two (2) |
| dispensings in any 30-day perio | od. | | |
| * Solution or suspension | 125 mg/5 cc | | cc |
| | 200 mg/5 cc | | CC |
| | 250 mg/5 cc | | cc |
| | 400 mg/5 cc 600 mg/5 cc | | cc cc |
| * Restricted to a maximum of two (2 | · · | 30-day period. | 00 |
| (NDC labeler code 00029 [SmithKlineBeecham] only.) | | | |
| | | -1 | |
| BUPROPION HCL | | | |
| Tablets | 75 mg | | ea |
| Custoined release tablet | 100 mg | | ea |
| Sustained release tablet | 100 mg 150 mg | | ea |
| | 200 mg | | ea ea |
| * + Sustained release tablet for smoking cessation | 150 mg | | ea |
| * Pharmacy must obtain a letter or certificate of enrollment for the patient from a behavioral modification smoking cessation program. Also restricted to a maximum quantity of 60 tablets per dispensing and therapy lasting up to 12 weeks from the dispensing date of the first prescription and two courses of therapy per 12-month period separated by six months. | | | |
| (NDC labeler code 00173 [GlaxoS | SmithKline] only.) | | |
| * DALTEPARIN SODIUM | | | |
| Injection, prefilled syringe | 2500 IU | | <u>cc</u> |
| | 5000 IU | | <u>cc</u> |
| * Prior authorization always required. | | | |
| * | | | |
| * LINEZOLID Tablets | 600 mg | | 00 |
| Suspension | 100 mg/5 cc | 150 cc | ea cc |
| Caoponoion | 100 1119/0 00 | 100 00 | |
| * Prior authorization always requ | ired. | | |

⁺ Frequency of billing requirement.

This information is reflected on manual replacement pages <u>drugs cdl p1a 7, 18, 36, 37 and 46</u> (Part 2), <u>drugs cdl p1b 12, 16, 41 and 55</u> (Part 2) and <u>drugs cdl p1c 6 and 36</u> (Part 2).

Unlisted Wheelchairs, Accessories and Replacement Parts: Corrected Reimbursement Methodology

An article that ran in the December 2003 Pharmacy *Medi-Cal Update 572* listed incorrect amounts for the aggregate Manufacturer's Suggested Retail Price (MSRP) for manual wheelchairs. The correct amounts are as follows:

Manual Wheelchairs

| Aggregate MSRP * | Percentage of MSRP |
|-------------------|--------------------|
| \$1 - \$1,500 | 90 |
| \$1,501 - \$4,000 | 85 |
| \$4,001 + | 80 |

^{*} The total aggregate MSRP includes the wheelchair base and all accessories billed for each date of service (for example, date of delivery).

Please refer to the December 2003 *Medi-Cal Update 572* for additional information on the reimbursement methodology for unlisted wheelchairs, accessories and replacement parts. *This information will be reflected in future manual replacement page updates.*

Intravenous Compound Drug Claims: Billing Update

Effective for dates of service on or after December 1, 2003, intravenous or intra-arterial compounded drugs may be billed with Route of Administration code 04 (injection) or Route of Administration code 14 (perfusion) using the 10-day Code I rule. The *Route of Administration* field is Box 23 of the *Compound Drug Pharmacy Claim Form* (30-4). Previous policy allowed only Route of Administration code 04.

Note: For additional information about the Code I rule, refer to the *Drugs: Contract Drugs List Introduction* section of the Part 2 manual.

Medical Supply Billing Codes: Policy Clarification

Effective for dates of service on or after February 1, 2004, Medi-Cal is clarifying what may be billed under medical supply billing codes 9930A and 9930D. Code 9930A covers feeding tubes not pre-attached to a bag and not used alone. Tubing with attached bags is not billable with this code. Code 9930D covers enteral feeding supply kit-syringe and enteral feeding supply kit-gravity. Codes 9930A and 9930D cover feeding sets that do not require a pump.

Any sets that use a pump may not be billed with codes 9930A and 9930D. These items must be billed with code 9999A (unlisted and miscellaneous medical supply) and require prior authorization. This information is reflected on provider manual page mc sup lst1 17 (Part 2).

Pharmacy Self-Certification: Policy Clarification

Self-certification for Other Health Coverage on pharmacy claims does not apply to medical supplies. This is a clarification of existing policy. The updated information is reflected on manual replacement pages <u>mc sup 1</u> (Part 2) and <u>oth hlth 8</u> (Part 2).

Instructions for Manual Replacement Pages Pharmacy (PH) Bulletin 573

December 2003

Part 2

Remove and replace: drugs cdl p1a 7/8, 17 thru 20 *, 35 thru 40, and 45/46

drugs cdl p1b 11/12, 15/16, 41/42 and 55

drugs cdl p1c 5/6, 35/36

drugs cdl p4 5/6 *, 13 thru 16 * and 19 *

mc sup 1/2 oth hlth 7/8

^{*} Pages updated due to ongoing manual updates